SCHEMBL4834622

SCHEMBL4834622

Cn1cc(C=O)c(-c2cccs2)n1

nearest known ligand 0.64

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
LMNA P02545 2/20 0.64
ALDH1A1 P00352 5/20 0.47
KDM4E B2RXH2 2/20 0.47
KMT2A Q03164 4/20 0.44
MEN1 O00255 3/20 0.44
SMN1; SMN2 Q16637 3/20 0.43
MAPT P10636 3/20 0.43
HPGD P15428 2/20 0.43
NPC1 O15118 2/20 0.43
RAB9A P51151 2/20 0.43
TP53 P04637 1/20 0.43
HSP90AA1 P07900 1/20 0.43
MAPK1 P28482 1/20 0.43
NTSR1 P30989 1/20 0.43
HTT P42858 1/20 0.43
RECQL P46063 1/20 0.43
NPSR1 Q6W5P4 1/20 0.43
DPP4 P27487 1/20 0.41
ERN1 O75460 5/20 0.41
PARP1 P09874 3/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4917849 0.78 KMT2A (0.70) LMNAALDH1A1KDM4EKMT2AMEN1
SCHEMBL26388657 0.77 LMNA (0.42) LMNAALDH1A1KDM4EKMT2AMEN1
SCHEMBL31626636 0.75 LMNA (0.39) LMNAALDH1A1KDM4EKMT2AMEN1
SCHEMBL20718851 0.75 PTGS2 (0.64) LMNAALDH1A1KDM4EKMT2AMEN1
SCHEMBL15333086 0.74 LMNA (0.38) LMNAALDH1A1KMT2AMEN1SMN1; SMN2
SCHEMBL21854198 0.74 ALDH1A1 (0.49) LMNAALDH1A1KDM4EKMT2AMEN1
SCHEMBL869929 0.73 PTGS2 (0.63) LMNAALDH1A1KDM4EKMT2AMEN1
SCHEMBL16344554 0.72 SMN1; SMN2 (0.59) LMNAALDH1A1KMT2ASMN1; SMN2MAPT
SCHEMBL4833180 0.72 KDM4E (0.46) LMNAALDH1A1KDM4EKMT2AMEN1
SCHEMBL1337388 0.71 ERN1 (0.43) LMNAALDH1A1KDM4EKMT2AMEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2025125829-A1 NORA INHIBITORS IMPERIAL COLLEGE INNOVATIONS LIMITED (GB) 2025-06-19 WO disclosed
US-20080287438-A1 Agent for preventing or treating neuropathy MOMOSE YU 2008-11-20 US disclosed
US-7423159-B2 Agent for preventing or treating neuropathy TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2008-09-09 US disclosed
CN-1731994-A Prophylactic and therapeutic agent for neuropathy TAKEDA CHEMICAL INDUSTRIES LTD (JP) 2006-02-08 CN disclosed
US-20060004069-A1 Agent for preventing or treating neuropathy TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2006-01-05 US disclosed
EP-1556032-A1 AGENT FOR PREVENTING OR TREATING NEUROPATHY Takeda Pharmaceutical Company Limited (JP) 2005-07-27 EP disclosed
WO-2004039365-A1 AGENT FOR PREVENTING OR TREATING NEUROPATHY TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2004-05-13 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060004069-A1 Agent for preventing or treating neuropathy NR2C2, NR0B2, NR2E1 LMNA 2405/4885ALDH1A1 2652/4885KDM4E 4406/4885
US-20080287438-A1 Agent for preventing or treating neuropathy NR2C2, NR0B2, NR2E1 LMNA 2405/4885ALDH1A1 2652/4885KDM4E 4406/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.